Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Increases By 37.6%

Nanobiotix S.A. (NASDAQ:NBTX) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 29,300 shares, a growth of 37.6% from the February 13th total of 21,300 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average trading volume of 32,500 shares, the short-interest ratio is presently 0.9 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NBTX. Geode Capital Management LLC bought a new position in Nanobiotix during the 4th quarter valued at approximately $29,000. Millennium Management LLC bought a new position in Nanobiotix during the 4th quarter valued at approximately $39,000. Jane Street Group LLC bought a new position in Nanobiotix during the 4th quarter valued at approximately $73,000. Finally, OLD Mission Capital LLC bought a new position in Nanobiotix during the 4th quarter valued at approximately $139,000. Institutional investors own 38.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, UBS Group raised Nanobiotix to a “hold” rating in a research report on Monday, February 17th.

Nanobiotix Stock Up 2.8 %

NBTX stock traded up $0.09 on Monday, reaching $3.33. 9,265 shares of the company traded hands, compared to its average volume of 21,943. Nanobiotix has a one year low of $2.76 and a one year high of $7.51. The firm has a fifty day simple moving average of $3.44 and a 200-day simple moving average of $3.94.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.